May 8th- Beyond the webinar: Multiple Myeloma in 2026: Innovation Meets Reality – Lessons from the Australian Experience

CME Congresses .

May 8th- Beyond the webinar: Multiple Myeloma in 2026: Innovation Meets Reality – Lessons from the Australian Experience

May 7th- Beyond the webinar: Busulfan in Hematology – From Empiricism to Precision Conditioning

CME Congresses .

May 7th- Beyond the webinar: Busulfan in Hematology – From Empiricism to Precision Conditioning

May 4th- Reinventing Drug Delivery in Multiple Myeloma: The Rise of the On-Body Injector for Isatuximab

CME Congresses .

May 4th- Reinventing Drug Delivery in Multiple Myeloma: The Rise of the On-Body Injector for Isatuximab

May 1st- Beyond the Webinar: CAR-T Cells- From Breakthrough to Global Transformation

CME Congresses .

May 1st- Beyond the Webinar: CAR-T Cells- From Breakthrough to Global Transformation

May 5th- Dr. Neta Nevo- Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel

CME Congresses .

May 5th- Dr. Neta Nevo- Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel

April 27th- Prof. Robert Zeiser- Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML

CME Congresses .

April 27th- Prof. Robert Zeiser- Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML

April 22nd- Hepta-Refractory Myeloma: When Targets Disappear

CME Congresses .

April 22nd- Hepta-Refractory Myeloma: When Targets Disappear

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

CME Congresses .

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

CME Congresses .

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

CME Congresses .

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact